Comparison of Pleural Drainage Systems on Reducing Pleural Effusion Formation Following Lung Resection
NCT ID: NCT01776372
Last Updated: 2014-05-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
103 participants
INTERVENTIONAL
2013-01-31
2013-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Digital Versus Analog Pleural Drainage Following Pulmonary Resection
NCT01775657
Digital Versus Analog Pleural Drainage in Patients With Pulmonary Air Leak
NCT01566032
Comparing Valve-regulated Pleural Drainage to Traditional Closed Chest Tube Drainage
NCT06410716
Tunneled Pleural Catheter in Partially Entrapped Lung
NCT00637676
Pleural Catheters Versus Thoracoscopic Pleurodesis
NCT01117740
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The following is a proposal for a randomized, controlled trial where patients will be randomized to have either a digital drainage system (intervention group) or non-digital drainage system, a conventional system currently used to drain the pleural space (the control group) after major lung resection for malignancy. The primary outcome of this study is comparing the overall amounts of pleural fluid drainage after major lung resection using two different chest tube drainage systems. Secondary outcomes will include measurement in time (hours) that chest tubes remain in-situ before removal following an operative procedure, and overall reduction in the length of stay (LOS) of patients; 90 days overall mortality and morbidity; occurrence of dyspnea related to the reoccurrence of pleural effusion; clinically significant reintervention needed (thoracocentesis, re-insertion of chest drain(s) and number and type of imaging studies required which are related to potential re-accumulation of pleural effusion); readmission rates within 1 month of discharge; comparison of pleural fluid/plasma protein ratio and inflammatory mediators (IL-6, IL-8, IL-10, IL-1RA, TNF-α) between the two groups, a potential indicator for differences in pleural inflammation and permeability between the two groups.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
SUPPORTIVE_CARE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Digital thoracic drainage system
Medela Thopaz Thoracic Drainage System
Medela Thopaz Thoracic Drainage System
Non-digital thoracic drainage system
Atrium Express Dry Seal Chest Drain
Atrium Express Dry Seal Chest Drain
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Medela Thopaz Thoracic Drainage System
Atrium Express Dry Seal Chest Drain
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with suspected lung cancer or metastatic cancer to the lungs
* Surgery must include lung resection (Wedge; single or multiple, lobectomy or bi-lobectomy) and mediastinal lymph nodes sampling or dissection
* Demonstrate an ability for understanding the study procedures
* Demonstrate willingness to remain on-study for the complete duration
* Must be able to give informed consent to participate at this study.
Exclusion Criteria
* Patients undergoing pneumonectomy
* Patients treated with neo-adjuvant chemotherapy and/or radiation prior to surgery
* Patients with previous lung resection on the ipsilateral side
* Patients with evidence of chronic heart failure (i.e. NYHA class III, IV; current treatment with diuretics for heart failure, and/or LVEF \<35%)
* Patients with chronic renal failure (i.e. estimated CCr of \< 50ml/min/m2)
* Patients with history of or ongoing liver disease, expressed by ascites or previous peritoneal tapping for ascites.
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
McMaster University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yaron Shargall, MD FRCSC
Role: PRINCIPAL_INVESTIGATOR
McMaster University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St. Joseph's Healthcare Hamilton
Hamilton, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
R.P. 12-3800
Identifier Type: OTHER
Identifier Source: secondary_id
SJHHPleuralDrainageComparsion
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.